M.MongeonR.LahmannC.KovealD.ZuckerH.YellenG
Your gastrointestinal tract adapts to slower gastric emptying and adjusted hunger hormones through gradual exposure rather than sudden pharmacological shock
Semaglutide's market dominance reflects its superior clinical profile, particularly its once-weekly dosing convenience, dual diabetes and weight management approvals, and groundbreaking cardiovascular outcomes data from the SELECT trial demonstrating a 20% MACE risk reduction
All clinical data cited comes from published Phase 2 and Phase 3 trial results and press releases from ongoing studies
Tirzepatide* (Higher dosage vial after titration) $449 For Month 3+ (includes medication, diet and exercise plan, as well as a consultation with monthly follow-up appointments) *Start Same Day as your Consult
Getty Images Emerging vision risks linked to semaglutide, tirzepatide Recent data points to potential ophthalmic complications, including optic neuropathy and maculopathy, in patients treated with semaglutide and tirzepatide
